報價延遲最少15分鐘:2025/09/04 04:01 EDT
盤前時段
|
||||
|
0.6 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.93/-0.97
|
|
企業價值
23.30M
|
| 資產負債 |
|
每股賬面淨值
1.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
636.00K
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 04:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. |
